企業プロフィール
KalVista Pharmaceuticals, Inc. 株価・ニュース・カタリスト
- ティッカー:
- KALV
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United Kingdom
株価パフォーマンス
26.95 USD (+0.04%)
終値
最終更新: 2026年6月3日
1.43B USD
時価総額
株価変動の要因
Current closing-price context is not available for KALV.
企業概要
Hereditary Angioedema Company
KalVista Pharmaceuticals develops and commercializes therapies for hereditary angioedema. Its lead franchise is based on oral inhibition of plasma kallikrein during acute attacks.
EKTERLY
EKTERLY, or sebetralstat, is the first approved oral on-demand treatment for hereditary angioedema attacks. It is approved in multiple countries for patients age 12 and older and is commercialized directly or through regional partners.
Pediatric Expansion
The Phase 3 KONFIDENT-KID trial has completed enrollment in children ages 2–11. KalVista plans to use the study to extend oral on-demand treatment to younger patients and pursue additional global filings.
今後のカタリスト
- U.S. NDA filing for EKTERLY in children ages 2–11 planned for the third quarter of 2026.
- Potential U.S. pediatric launch anticipated in 2027, subject to approval.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。